Vaccination is one of the most cost-effective and safest ways to prevent diseases. Pneumococcus is one of the major causes of blood infection, pneumonia, sinusitis, meningitis, and otitis media. It is also a leading infectious disease. However, it can be prevented with the help of vaccination. Majority of countries have pneumococcal vaccines in their national immunization program for children aged under 1 year. Increase in pneumococcal diseases due to causative serotype drives the need for vaccines with broader coverage. Hence, demand for new pneumococcal vaccines with wider serotype coverage is rising.
Despite the availability of antibiotic therapy against pneumococcal disease, it remains a significant cause of death among people with increased susceptibility such as the elderly and people suffering from immunosuppressive conditions or chronic illness. However, prevalence of pneumococcal disease has declined in countries that introduced pneumococcal conjugate vaccines (PCV). Meanwhile, efforts are underway to introduce pneumococcal vaccines in other countries as well. Companies also plan to introduce new and affordable PCVs, especially for the developing countries. There has also been an increase in investment in research and development to develop new vaccines at lower cost.
The global pneumococcal vaccines market has been segmented based on product type, distribution channel, sector, and region. In terms of product type, the global market has been classified into Synflorix, Prevenar-13, PCV 13 (pipeline), V114 (Merck), PCV-20 (Pfizer), PCV-10 (SII), and PPSV- 23. Each of the product segments has been divided into pediatric and adults. Based on distribution channel, the global market has been categorized into wholesalers (pharmacy channel), specialized companies, public authorities, and others. In terms of sector, the global pneumococcal vaccines market has been bifurcated into private and public. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Rest of the World.
In terms of product type, Prevenar-13 dominated the global market in 2017, accounting for 77.3% share. Prevenar-13 is Pfizer, Inc.’s largest brand, which has been one of the most widely adopted 13-valent PCV vaccines across the world. However, higher cost of the vaccine and entry of new vaccines are projected to hamper sales from 2018 to 2026.
Based on distribution channel, the wholesalers (pharmacy channel) segment dominated the global pneumococcal vaccines market in 2017. Vaccine distribution in Europe and some countries in Asia Pacific follows a traditional pharmaceutical supply chain, and wholesalers are dominant in these countries. However, shortage of vaccines and difficulty in accessing essential vaccines in several countries have led to the entry of public authorities in the overall supply and distribution of vaccines. Hence, the wholesalers segment is expected to lose market share from 2018 to 2026. Increase in participation by regional and national governments along with non-profit organizations for availability, supply, and distribution of pneumococcal vaccines in emerging countries is anticipated to boost the growth of the public segment between 2018 and 2026.
In terms of sector, the private segment dominated the global pneumococcal vaccines market in 2017. The U.S., the U.K., Germany, and other major countries in Europe, along with emerging markets such as India are dominated by the private sector engaged in procurement, distribution, and pricing of pneumococcal vaccines. Entry of non-profit organizations such as GAVI, UNICEF, and WHO is projected to result in higher procurement of vaccines in terms of volume (doses procured) by the public sector. However, involvement of these authorities in price negotiations of sourced vaccines from manufacturers is likely to lead to lower share of the public sector in terms of revenue (US$ Mn) of the global pneumococcal vaccines market from 2018 to 2026.
In terms of region, the global pneumococcal vaccines market has been segmented into North America, Europe, Latin America, Asia Pacific, and Rest of the World. North America dominated the global market in 2017, accounting for 57.9% share owing to strong sales of Prevenar-13 in the U.S. Pneumococcal conjugated vaccine (PCV) has been part of routine vaccine immunization in Canada and the U.S. since 2000. These countries have also witnessed highly-effective results since the vaccine was introduced. Investments by government organizations and private companies have also increased for the promotion of vaccination and research & development of new vaccines. North America has also emerged as a primary center for several vaccine manufacturers. PCV is also a part of vaccination programs in countries such as the Netherlands, Germany, Slovakia, Albania, Greece, and Serbia. Increase in incidence of pneumococcal diseases in countries in APEJ also presents an opportunity for companies producing pneumococcal vaccines. Brazil is witnessing a significant increase in pneumococcal diseases. Hence, various programs are being introduced in Brazil to increase vaccine coverage.
Major players operating in the global pneumococcal vaccines market include Pfizer, Inc., Merck & Co., Inc., SK Chemicals, Serum Institute of India Pvt. Ltd., Chengdu Institute of Biological Products Co., Ltd., GlaxoSmithKline plc, Sanofi, and Walvax Biotechnology Co., Ltd.
Continuous Progress in Conjugate Vaccine Development Boosts Pneumococcal Vaccines Market
The growth in the pneumococcal vaccines market has been largely spearheaded by continuous progress in conjugate vaccine development. The invasive as well non-invasive pneumococcal disease have been a major cause of morbidity in children and toddlers. High-income countries have been careful about conducting and supporting nationwide immunization programs provide protection against Streptococcus pneumoniae infections. On the other hand, low- and middle-income countries (LMICs), where the mortality is high in infants and toddlers, vaccination strategies have failed to provide protection due to the compromised resource settings. On the other hand, in high income countries, pneumococcal vaccination programs have led to development of herd immunity. As a result, strides in the pneumococcal vaccines market have led to substantial reduction of morbidity and mortality from invasive pneumococcal disease. However, in both these settings, the market has been witnessing an unmet need due to numerous factors: lack of access to optimal vaccine formulations and lack of understanding of immunological markers. To overcome the various limitations, market players are exploring innovative approaches and novel formulations. A case in point is growing focus of vaccine manufacturers on country-specific serotype-specific immunogenicity in developing vaccine formulations. Ongoing research pertaining to protein-based vaccines is expected to bring some of the promising product lines.
The current pandemic is being defined by Sars-CoV-2 virus infections and the rise in case loads in several countries across the world. The debilitating impact the pandemic has been making on the human health has challenged the existing healthcare infrastructure of even the most developed nations. The vaccination programs have received a new impetus from continuous efforts by governments, in collaboration with industry players, to make Covid-19 vaccines make available to public at large. The vaccines are currently viewed as the most powerful strategy in combating the morbidity and mortality of the novel coronavirus. Ongoing research in vaccine development are exploring new strategies on war-footing pace to unveil more efficacious formulations that can help develop herd immunity in the worldwide population. All these approaches are also influencing the growth of the pneumococcal vaccines market.
The global pneumococcal vaccines market has been segmented as below:
|
by Product Type |
|
|
by Distribution Channel |
|
|
by Sector |
|
|
by Region |
|
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Pneumococcal Vaccines Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
3.2. Global Pneumococcal Vaccines Market: Market Snapshot, 2016
4. Market Overview
4.1. Overview
4.2. Global Pneumococcal Vaccines Market Size (US$ Mn) Forecast, 2016–2026
4.3. Global Pneumococcal Vaccines Market Outlook
4.4. Approved & Pipeline Products Snapshot
5. Market Dynamics
5.1. Drivers
5.1.1. Government participation in design & implementation of comprehensive vaccination programs
5.1.2. Increase in investments by public & private players in R&D of conjugate pneumococcal vaccines
5.2. Restraints
5.2.1. Longer timeline and high cost associated with development of pneumococcal vaccines
5.3. Opportunities
5.3.1. Development of multivalent conjugated vaccines with different serotypes
5.4. Trends
5.4.1. Public-Private Partnerships
6. Global Pneumococcal Vaccines Market Analysis, by Product Type
6.1. Introduction
6.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Product Type
6.3. Pneumococcal Vaccines Market Analysis, by Product Type
6.3.1. Synflorix
6.3.1.1. Pediatric
6.3.1.2. Adult
6.3.2. Prevenar-13
6.3.2.1. Pediatric
6.3.2.2. Adult
6.3.3. PCV 13 (pipeline)
6.3.3.1. Pediatric
6.3.3.2. Adult
6.3.4. V114 (Merck)
6.3.4.1. Pediatric
6.3.4.2. Adult
6.3.5. PCV-20 (Pfizer)
6.3.5.1. Pediatric
6.3.5.2. Adult
6.3.6. PCV-10 (SII)
6.3.6.1. Pediatric
6.3.6.2. Adult
6.3.7. PPSV- 23
6.3.7.1. Pediatric
6.3.7.2. Adult
7. Global Pneumococcal Vaccines Market Analysis, by Distribution Channel
7.1. Introduction
7.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
7.3. Pneumococcal Vaccines Market Analysis, by Distribution Channel
7.3.1. Wholesalers
7.3.2. Specialized Companies
7.3.3. Public Authorities
7.3.4. Others
8. Global Pneumococcal Vaccines Market Analysis, by Sector
8.1. Introduction
8.2. Global Pneumococcal Vaccines Market Value Share Analysis, by Sector
8.3. Pneumococcal Vaccines Market Analysis, by Sector
8.3.1. Public
8.3.2. Private
9. U.S. Pneumococcal Vaccines Market Analysis
9.1. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Product Type
9.2. U.S. Pneumococcal Vaccines Market Forecast, by Product Type
9.2.1. Prevanar-13
9.2.2. V114
9.2.3. PCV-20
9.2.4. Pneumovax-23
9.3. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
9.4. U.S. Pneumococcal Vaccines Market Forecast, by Distribution Channel
9.4.1. Wholesalers
9.4.2. Specialized Companies
9.4.3. Public Authorities
9.4.4. Others
9.5. U.S. Pneumococcal Vaccines Market Value Share Analysis, by Sector
9.6. U.S. Pneumococcal Vaccines Market Forecast, by Sector
9.6.1. Private
9.6.2. Public
10. Canada Pneumococcal Vaccines Market Analysis
10.1. Canada Pneumococcal Vaccines Market Value Share Analysis, by Product Type
10.2. Canada Pneumococcal Vaccines Market Forecast, by Product Type
10.2.1. Prevenar-13
10.2.2. Synflorix
10.2.3. V-114
10.2.4. Pneumo - 23
10.2.5. Pnuemovax-23
10.3. Canada Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
10.4. Canada Pneumococcal Vaccines Market Forecast, by Distribution Channel
10.4.1. Wholesalers
10.4.2. Specialized Companies
10.4.3. Public Authorities
10.4.4. Others
10.5. Canada Pneumococcal Vaccines Market Value Share Analysis, by Sector
10.6. Canada Pneumococcal Vaccines Market Forecast, by Sector
10.6.1. Private
10.6.2. Public
11. Germany Pneumococcal Vaccines Market Analysis
11.1. Germany Pneumococcal Vaccines Market Value Share Analysis, by Product Type
11.2. Germany Pneumococcal Vaccines Market Forecast, by Product Type
11.2.1. Prevenar-13
11.2.2. Synflorix
11.2.3. V-114
11.2.4. PCV-20
11.2.5. Pnuemovax-23
11.3. Germany Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
11.4. Germany Pneumococcal Vaccines Market Forecast, by Distribution Channel
11.4.1. Wholesalers
11.4.2. Specialized Companies
11.4.3. Public Authorities
11.4.4. Others
11.5. Germany Pneumococcal Vaccines Market Value Share Analysis, by Sector
11.6. Germany Pneumococcal Vaccines Market Forecast, by Sector
11.6.1. Private
11.6.2. Public
12. U.K. Pneumococcal Vaccines Market Analysis
12.1. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Product Type
12.2. U.K. Pneumococcal Vaccines Market Forecast, by Product Type
12.2.1. Prevenar-13
12.2.2. Synflorix
12.2.3. V-114
12.2.4. PCV-20
12.2.5. Pnuemovax-23
12.3. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
12.4. U.K. Pneumococcal Vaccines Market Forecast, by Distribution Channel
12.4.1. Wholesalers
12.4.2. Specialized Companies
12.4.3. Public Authorities
12.4.4. Others
12.5. U.K. Pneumococcal Vaccines Market Value Share Analysis, by Sector
12.6. U.K. Pneumococcal Vaccines Market Forecast, by Sector
12.6.1. Private
12.6.2. Public
13. France Pneumococcal Vaccines Market Analysis
13.1. France Pneumococcal Vaccines Market Value Share Analysis, by Product Type
13.2. France Pneumococcal Vaccines Market Forecast, by Product Type
13.2.1. Prevenar-13
13.2.2. Synflorix
13.2.3. V-114
13.2.4. PCV-20
13.2.5. Pnuemovax-23
13.3. France Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
13.4. France Pneumococcal Vaccines Market Forecast, by Distribution Channel
13.4.1. Wholesalers
13.4.2. Specialized Companies
13.4.3. Public Authorities
13.4.4. Others
13.5. France Pneumococcal Vaccines Market Value Share Analysis, by Sector
13.6. France Pneumococcal Vaccines Market Forecast, by Sector
13.6.1. Private
13.6.2. Public
14. Italy Pneumococcal Vaccines Market Analysis
14.1. Italy Pneumococcal Vaccines Market Value Share Analysis, by Product Type
14.2. Italy Pneumococcal Vaccines Market Forecast, by Product Type
14.2.1. Prevenar-13
14.2.2. Synflorix
14.2.3. V-114
14.2.4. PCV-20
14.2.5. Pnuemovax-23
14.3. Italy Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
14.4. Italy Pneumococcal Vaccines Market Forecast, by Distribution Channel
14.4.1. Wholesalers
14.4.2. Specialized Companies
14.4.3. Public Authorities
14.4.4. Others
14.5. Italy Pneumococcal Vaccines Market Value Share Analysis, by Sector
14.6. Italy Pneumococcal Vaccines Market Forecast, by Sector
14.6.1. Private
14.6.2. Public
15. Spain Pneumococcal Vaccines Market Analysis
15.1. Spain Pneumococcal Vaccines Market Value Share Analysis, by Product Type
15.2. Spain Pneumococcal Vaccines Market Forecast, by Product Type
15.2.1. Prevenar-13
15.2.2. Synflorix
15.2.3. V-114
15.2.4. PCV-20
15.2.5. Pnuemovax-23
15.3. Spain Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
15.4. Spain Pneumococcal Vaccines Market Forecast, by Distribution Channel
15.4.1. Wholesalers
15.4.2. Specialized Companies
15.4.3. Public Authorities
15.4.4. Others
15.5. Spain Pneumococcal Vaccines Market Value Share Analysis, by Sector
15.6. Spain Pneumococcal Vaccines Market Forecast, by Sector
15.6.1. Private
15.6.2. Public
16. Belgium Pneumococcal Vaccines Market Analysis
16.1. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Product Type
16.2. Belgium Pneumococcal Vaccines Market Forecast, by Product Type
16.2.1. Prevenar-13
16.2.2. Synflorix
16.2.3. V-114
16.2.4. PCV-20
16.2.5. Pnuemovax-23
16.3. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
16.4. Belgium Pneumococcal Vaccines Market Forecast, by Distribution Channel
16.4.1. Wholesalers
16.4.2. Specialized Companies
16.4.3. Public Authorities
16.4.4. Others
16.5. Belgium Pneumococcal Vaccines Market Value Share Analysis, by Sector
16.6. Belgium Pneumococcal Vaccines Market Forecast, by Sector
16.6.1. Private
16.6.2. Public
17. India Pneumococcal Vaccines Market Analysis
17.1. India Pneumococcal Vaccines Market Value Share Analysis, by Product Type
17.2. India Pneumococcal Vaccines Market Forecast, by Product Type
17.2.1. Prevenar-13
17.2.2. Synflorix
17.2.3. SIIL PCV-10
17.2.4. PCV-20
17.2.5. Pnuemovax-23
17.3. India Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
17.4. India Pneumococcal Vaccines Market Forecast, by Distribution Channel
17.4.1. Wholesalers
17.4.2. Specialized Companies
17.4.3. Public Authorities
17.4.4. Others
17.5. India Pneumococcal Vaccines Market Value Share Analysis, by Sector
17.6. India Pneumococcal Vaccines Market Forecast, by Sector
17.6.1. Private
17.6.2. Public
18. China Pneumococcal Vaccines Market Analysis
18.1. China Pneumococcal Vaccines Market Value Share Analysis, by Product Type
18.2. China Pneumococcal Vaccines Market Forecast, by Product Type
18.2.1. Prevenar-13
18.2.2. PCV 13 (pipeline)
18.2.3. PPSV 23
18.3. China Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
18.4. China Pneumococcal Vaccines Market Forecast, by Distribution Channel
18.4.1. Wholesalers
18.4.2. Specialized Companies
18.4.3. Public Authorities
18.4.4. Others
18.5. China Pneumococcal Vaccines Market Value Share Analysis, by Sector
18.6. China Pneumococcal Vaccines Market Forecast, by Sector
18.6.1. Private
18.6.2. Public
19. Japan Pneumococcal Vaccines Market Analysis
19.1. Japan Pneumococcal Vaccines Market Value Share Analysis, by Product Type
19.2. Japan Pneumococcal Vaccines Market Forecast, by Product Type
19.2.1. Prevenar-13
19.2.2. Synflorix
19.2.3. PPSV 23
19.3. Japan Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
19.4. Japan Pneumococcal Vaccines Market Forecast, by Distribution Channel
19.4.1. Wholesalers
19.4.2. Specialized Companies
19.4.3. Public Authorities
19.4.4. Others
19.5. Japan Pneumococcal Vaccines Market Value Share Analysis, by Sector
19.6. Japan Pneumococcal Vaccines Market Forecast, by Sector
19.6.1. Private
19.6.2. Public
20. Australia Pneumococcal Vaccines Market Analysis
20.1. Australia Pneumococcal Vaccines Market Value Share Analysis, by Product Type
20.2. Australia Pneumococcal Vaccines Market Forecast, by Product Type
20.2.1. Prevenar-13
20.2.2. Synflorix
20.2.3. V114
20.2.4. Pnuemovax-23
20.3. Australia Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
20.4. Australia Pneumococcal Vaccines Market Forecast, by Distribution Channel
20.4.1. Wholesalers
20.4.2. Specialized Companies
20.4.3. Public Authorities
20.4.4. Others
20.5. Australia Pneumococcal Vaccines Market Value Share Analysis, by Sector
20.6. Australia Pneumococcal Vaccines Market Forecast, by Sector
20.6.1. Private
20.6.2. Public
21. New Zealand Pneumococcal Vaccines Market Analysis
21.1. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Product Type
21.2. New Zealand Pneumococcal Vaccines Market Forecast, by Product Type
21.2.1. Prevenar-13
21.2.2. Synflorix
21.2.3. Pnuemovax-23
21.3. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
21.4. New Zealand Pneumococcal Vaccines Market Forecast, by Distribution Channel
21.4.1. Wholesalers
21.4.2. Specialized Companies
21.4.3. Public Authorities
21.4.4. Others
21.5. New Zealand Pneumococcal Vaccines Market Value Share Analysis, by Sector
21.6. New Zealand Pneumococcal Vaccines Market Forecast, by Sector
21.6.1. Private
21.6.2. Public
22. Brazil Pneumococcal Vaccines Market Analysis
22.1. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Product Type
22.2. Brazil Pneumococcal Vaccines Market Forecast, by Product Type
22.2.1. Prevenar-13
22.2.2. Synflorix
22.2.3. Pnuemovax-23
22.3. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
22.4. Brazil Pneumococcal Vaccines Market Forecast, by Distribution Channel
22.4.1. Wholesalers
22.4.2. Specialized Companies
22.4.3. Public Authorities
22.4.4. Others
22.5. Brazil Pneumococcal Vaccines Market Value Share Analysis, by Sector
22.6. Brazil Pneumococcal Vaccines Market Forecast, by Sector
22.6.1. Private
22.6.2. Public
23. Mexico Pneumococcal Vaccines Market Analysis
23.1. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Product Type
23.2. Mexico Pneumococcal Vaccines Market Forecast, by Product Type
23.2.1. Prevenar-13
23.2.2. Synflorix
23.2.3. Pnuemovax-23
23.3. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
23.4. Mexico Pneumococcal Vaccines Market Forecast, by Distribution Channel
23.4.1. Wholesalers
23.4.2. Specialized Companies
23.4.3. Public Authorities
23.4.4. Others
23.5. Mexico Pneumococcal Vaccines Market Value Share Analysis, by Sector
23.6. Mexico Pneumococcal Vaccines Market Forecast, by Sector
23.6.1. Private
23.6.2. Public
24. Rest of the World Pneumococcal Vaccines Market Analysis
24.1. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Product Type
24.2. Rest of the World Pneumococcal Vaccines Market Forecast, by Product Type
24.2.1. Prevenar-13
24.2.2. Synflorix
24.2.3. V-114
24.2.4. PCV-20
24.2.5. PCV-10 (SII)
24.2.6. Pnuemovax-23
24.3. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Distribution Channel
24.4. Rest of the World Pneumococcal Vaccines Market Forecast, by Distribution Channel
24.4.1. Wholesalers
24.4.2. Specialized Companies
24.4.3. Public Authorities
24.4.4. Others
24.5. Rest of the World Pneumococcal Vaccines Market Value Share Analysis, by Sector
24.6. Rest of the World Pneumococcal Vaccines Market Forecast, by Sector
24.6.1. Private
24.6.2. Public
24.7. Rest of the World Pneumococcal Vaccines Market Forecast, by Region
25. Competition Landscape
25.1. Global Pneumococcal Vaccines Market Share Analysis, by Company (2017)
25.2. Company Profiles
25.2.1. Pfizer, Inc.
25.2.2. Merck & Co., Inc.
25.2.3. SK Chemicals
25.2.4. Serum Institute of India Pvt. Ltd.
25.2.5. Chengdu Institute of Biological Products Co., Ltd.
25.2.6. GlaxoSmithKline plc
25.2.7. Sanofi
25.2.8. Walvax Biotechnology Co., Ltd.
List of Tables
TABLE 1 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 2 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 3 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 4 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 5 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 6 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 7 U.S. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 8 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 9 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 10 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 11 Canada Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 12 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 13 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 14 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 15 Germany Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 16 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 17 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 18 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 19 U.K. Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 20 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 21 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 22 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 23 France Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 24 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 25 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 26 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 27 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 28 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 29 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 30 Spain Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 31 Italy Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 32 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 33 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 34 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 35 Belgium Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 36 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 37 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 38 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 39 India Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 40 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 41 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 42 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 43 China Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 44 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 45 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 46 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 47 Japan Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 48 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 49 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 50 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 51 Australia Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 52 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 53 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 54 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 55 New Zealand Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 56 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 57 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 58 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 59 Brazil Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 60 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 61 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 62 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 63 Mexico Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 64 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 65 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
TABLE 66 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
TABLE 67 Rest of the World (RoW) Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Sector, 2016–2026
TABLE 68 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Region, 2016–2026
TABLE 69 North America Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country, 2016–2026
TABLE 70 Europe Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
TABLE 71 Asia Pacific Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
TABLE 72 Latin America Pneumococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
List of Figures
FIG. 1 Global Pneumococcal Vaccines Market Value (US$ Mn) Forecast, 2016–2026
FIG. 2 Global Pneumococcal Vaccines Market Value Share (%), by Product Type (2017)
FIG. 3 Global Pneumococcal Vaccines Market Value Share (%), by Sector (2017)
FIG. 4 Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel (2017)
FIG. 5 Global Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 6 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 10-Valent, 2016–2026
FIG. 7 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 10-Valent (pipeline), 2016–2026
FIG. 8 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 13-Valent, 2016–2026
FIG. 9 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 13-Valent (pipeline), 2016–2026
FIG. 10 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 15-Valent (pipeline), 2016–2026
FIG. 11 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 20-Valent (pipeline), 2016–2026
FIG. 12 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by 23-Valent, 2016–2026
FIG. 13 Global Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 14 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Wholesalers, 2016–2026
FIG. 15 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialized Companies, 2016–2026
FIG. 16 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Public Authorities, 2016–2026
FIG. 17 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016–2026
FIG. 18 Global Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 19 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Public, 2016–2026
FIG. 20 Global Pneumococcal Vaccines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Private, 2016–2026
FIG. 21 U.S. Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 22 U.S. Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 23 U.S. Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 24 Canada Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 25 Canada Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 26 Canada Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 27 Germany Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 28 Germany Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 29 Germany Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 30 U.K. Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 31 U.K. Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 32 U.K. Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 33 France Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 34 France Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 35 France Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 36 Italy Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 37 Italy Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 38 Italy Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 39 Spain Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 40 Spain Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 41 Spain Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 42 Belgium Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 43 Belgium Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 44 Belgium Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 45 India Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 46 India Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 47 India Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 48 China Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 49 China Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 50 China Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 51 Japan Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 52 Japan Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 53 Japan Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 54 New Zealand Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 55 Australia Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 56 Australia Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 57 New Zealand Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 58 New Zealand Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 59 New Zealand Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 60 Brazil Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 61 Brazil Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 62 Brazil Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 63 Mexico Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 64 Mexico Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 65 Mexico Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 66 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Product Type, 2018 and 2026
FIG. 67 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Distribution Channel, 2018 and 2026
FIG. 68 Rest of the World (RoW) Pneumococcal Vaccines Market Value Share (%), by Sector, 2018 and 2026
FIG. 69 Global Pneumococcal Vaccines Market Share (%) and Market Share Range (%), by Company, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pneumococcal Vaccines Market Analysis till 2026
